 |
|
|
| |
Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study)
|
| |
| |
EACS 2021 Oct 27-30
H.-J. Stellbrink1, E. DeJesus2, S. Segal-Maurer3, A. Castagna4, A. Avihingsanon5, J.L. Blanco Arevalo6, F. Castelli7, A. Antinori8, Y. Yazdanpanah9, S. Ronot-Bregigeon10, H. Wang11, N. Margot11, H. Dvory-Sobol11, M.S. Rhee11, J. Baeten11, J.-M. Molina12
1ICH Study Center GmbH, Hamburg, Germany, 2Orlando Immunology Center, Orlando, United States, 3NewYork-Presbyterian Queens, Flushing, United States, 4IRCCS Ospedale San Raffaele, Milano, Italy, 5Thai Red Cross AIDS Research Centre (HIV-NAT), Bangkok, Thailand, 6Hospital Clinic de Barcelona, Barcelona, Spain, 7University of Brescia, Brescia, Italy, 8Lazzaro Spallanzani (IRCCS), Roma, Italy, 9Hôpital Bichat-Claude Bernard, Paris, France, 10Hôpital Sainte Marguerite, Marseille, France, 11Gilead Sciences Inc., Foster City, United States, 12Hôpital Saint-Louis, Paris, France
|
| |
|
|
|
|
|
